Results from first large scale PRRT trial released
The results from the first large scale randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.
PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.
Two NET Abstracts Set for Presentation at Presidential Session of ECC 2015
At the European Cancer Conference in Vienna at the end of September 2015 - Two late breaking abstracts have been selected for presentation at the prestigious Presidential Session on Sunday, September 27, 2015. (Click here to download session PDF)
LATE-BREAKING ABSTRACT: Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study
Speaker: J. Yao (USA)
LATE-BREAKING ABSTRACT: 177-Lu-Dotatate significantly improves progression-free survival in patients with mid gut neuroendocrine tumours: Results of the phase III NETTER-1 trial
Speaker: P. Ruszniewski (France)
NorCal CarciNET will be in Vienna and will post updates on these important developments as well as other topics of interest for those living with NETS.
Lexicon Reports Positive Top-Line Results for Phase 3 Telotristat Etiprate Study
On August 3, 2015, Lexicon Pharmaceuticals, Inc. announced that the pivotal TELESTAR Phase 3 clinical trial met its primary endpoint, showing the benefit of oral telotristat etiprate in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Telotristat etiprate was discovered using Lexicon’s gene science, based on Nobel Prize-winning technology, and is the company’s first discovery to complete a pivotal Phase 3 clinical trial. If approved, telotristat etiprate would be the first oral treatment successfully developed for carcinoid syndrome and the first addition to the standard of care in more than 16 years.
NorCal CarciNET President awarded
On June 8, 2015, Josh Mailman, patient advocate, and president of the NorCal CarciNET Community, was honored with the 2015 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Presidential Distinguished Service Award. The award reads, "For substantial contributions to the SNMMI patient outreach program and leadership of the Patient Advocacy Advisory Board (PAAB)."
Patient Program at 3rd Theranostic World Congress
Thanks to grants from Caring for Carcinoid Foundation and Carcinoid Cancer Foundation, the Saturday sessions (March 14) at the 3rd Theranostics Congress will be free of charge for patients.
To learn more about the conference visit the conference website.
Funding was provided by NorCal CarciNET Community for recording the entire 3rd Theranostics World Congress.
To see the entire patient program click here.